Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy

NCT01146587 · Status: SUSPENDED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2015-06-08

No results posted yet for this study

Summary

The GangTrainer GT I and the Lokomat have proven their effectiveness on stroke Patients, but a comparison on the same controlled study population has not been made so far. Aim of the study will not only be to establish which device will work better on acute, non ambulatory stroke Patients in terms of regain of gait ability and motor function, but also clinical matters, like the efficacy of the treatment period. As a result of the trial it should be highlighted which kind of therapy has to be suggested for Patients comparable to the study population. A significant better outcome of one device in regard to the other will suggest to use one device more than the other for future treatments.

Conditions

  • Stroke, Acute

Interventions

DEVICE

GangTrainer GT1

30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

DEVICE

Lokomat

30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks

OTHER

Conventional Physiotherapy

60 minutes of Conventional Physiotherapy every workday for 8 weeks

Sponsors & Collaborators

  • Privatklinik Villa Melitta

    collaborator OTHER
  • Hochzirl Hospital

    collaborator OTHER
  • Krankenhaus Bozen

    collaborator OTHER
  • Krankenhaus Brixen

    collaborator OTHER
  • Krankenhaus Meran

    collaborator OTHER
  • Krankenhaus Bruneck

    collaborator OTHER
  • Claudiana Landesfachhochschule

    collaborator OTHER
  • Research Department for Neurorehabilitation South Tyrol

    lead OTHER

Principal Investigators

  • Andreas Waldner, MD · Privatklinik Villa Melitta

  • Christopher Tomelleri, MSc · Privatklinik Villa Melitta

  • Leopold Saltuari, MD PhD · Hochzirl Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2015-12-31
Completion
2016-02-29

Countries

  • Austria
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01146587 on ClinicalTrials.gov